title: Survival advantage with the addition of radiation therapy to chemotherapy in early stage peripheral T-cell lymphoma, not otherwise specified.
abstract: OBJECTIVE
  Early stage peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is rare. The purpose of this study was to evaluate the outcome of treatment as well as the potential role of radiation therapy in PTCL-NOS.
  
  
  METHODS
  Thirty-five patients with early stage PTCL-NOS were included. There were 13 patients with stage I disease and 22 with stage II. All patients except 1 received doxorubicin-based chemotherapy alone (n=13) or a combination of chemotherapy and radiation therapy (CMT) (n=21).
  
  
  RESULTS
  The 3-year overall survival (OS) and progression-free survival (PFS) rates for the entire group were 41.3% and 25.7%, respectively. The addition of radiation therapy to chemotherapy significantly improved OS and PFS in early stage PTCL-NOS. The 3-year OS and PFS rates were 49.7% and 33.3% for CMT, compared with 23.1% (P=.042) and 15.4% (P=.035) for chemotherapy alone, respectively. The prognosis for patients who achieved a complete response (CR) was significantly better than that observed in those who did not achieve a CR.
  
  
  CONCLUSIONS
  Despite the aggressive clinical course of early stage PTCL-NOS, additional radiation therapy has a significant impact on outcome. The integration of local radiation therapy into more effective systemic therapies may further improve survival.
authors.affiliation: Department of Radiation Oncology, Cancer Hospital and Institution, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, PR China.
authors.forename: Xi-Mei
authors.initials: XM
authors.lastname: Zhang
authors.forename: Ye-Xiong
authors.initials: YX
authors.lastname: Li
authors.forename: Wei-Hu
authors.initials: WH
authors.lastname: Wang
authors.forename: Jing
authors.initials: J
authors.lastname: Jin
authors.forename: Shu-Lian
authors.initials: SL
authors.lastname: Wang
authors.forename: Yue-Ping
authors.initials: YP
authors.lastname: Liu
authors.forename: Yong-Wen
authors.initials: YW
authors.lastname: Song
authors.forename: Hui
authors.initials: H
authors.lastname: Fang
authors.forename: Hua
authors.initials: H
authors.lastname: Ren
authors.forename: Li-Qiang
authors.initials: LQ
authors.lastname: Zhou
authors.forename: Xin-Fan
authors.initials: XF
authors.lastname: Liu
authors.forename: Zi-Hao
authors.initials: ZH
authors.lastname: Yu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy / Q000379:methods; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D055815:Young Adult
chemical_list: D004317:Doxorubicin